Fig. 6. A80.2HCl potentiates the therapeutic efficacy of CDK4/6i.
a T24 cells treated with the indicated drugs were harvested for RNA-seq analysis, and heatmap showing the differential expression of the indicated pathway genes. b Venn diagram showing the overlapping downregulated genes after the indicated treatment of T24 cells. c Pathway analysis of 1609 genes downregulated after A80.2HCl + palbociclib treatment. Differentially regulated genes with more than 2-fold change were included in this pathway analysis. Color represents the level of significance, and P value adjusted. Data is analyzed by standard accumulative hypergeometric statistical. T24 (d) and UMUC14 (e) cells treated with the indicated drugs were harvested for cell viability assays. Data were shown as the mean ± SEM of three independent experiments (n = 3). T24 and UMUC14 cells treated with the indicated drugs were harvested for colony formation assay (f). In g, data were shown as the mean ± SD of three independent experiments (n = 3). Two-tailed unpaired Student’s t-test. P values based on the order of appearance: 0.0065, 0.0024, 0.9214 and 0.0003. h T24 cells were injected s.c. into the right flank of NSG mice, which were treated with the indicated drugs. Tumor volume was measured at the indicated time points. Data were shown as the mean ± SD of five mice (n = 5). Two-way ANOVA (two-sided). P values based on the order of appearance: 0.0235 and 0.0048. i Drug sensitivity analysis with mini-PDX models of breast cancer tissues with MYC amplification. Data were shown as the mean ± SD of six mice (n = 6). Two-tailed unpaired Student’s t-test. P values based on the order of appearance: 0.3279, and 0.0005. Source data are provided in this paper.